Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease

Circulation

Volumn 96, Issue 1, 1997, Pages 174-182

  Zhuo, Jia Long ^a   Froomes, Paul ^a,b   Casley, David ^a   Liu, James J ^a,b   Murone, Carmel ^a   Chai, Siew Y ^a   Buxton, Brian ^a,b   Mendelsohn, Frederick A O ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Angiotensin; Cardiovascular disease; Endothelium; Vessels

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; PERINDOPRIL;

ADULT; ADVENTITIA; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME INHIBITION; HUMAN; INTERNAL MAMMARY ARTERY; ISCHEMIC HEART DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

AGED; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUTORADIOGRAPHY; ENDOTHELIUM, VASCULAR; HEMODYNAMIC PROCESSES; HUMANS; INDOLES; MAMMARY ARTERIES; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PEPTIDYL-DIPEPTIDASE A; PERINDOPRIL;

EID: 0343990799     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1987;79:1-6.
2. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. Circ Res. 1991;68:905-921.
3. Johnston CI. The renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens. 1992;10(suppl 7):S13-S26.
4. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol. 1992;54:227-241.
5. Boadle MC, Hughes J, Roth RH. Angiotensin accelerates catecholamine biosynthesis in sympathetically innervated tissues. Nature. 1969;222:987-988.
6. Mombouli JV, Vanhoutte PM. Endothelium-derived hyperpolarizing factors and the potentiation of kinins by converting enzyme inhibitors. Am J Hypertens. 1995;8:19S-27S.
7. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69:475-482.
8. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens. 1991;9:3-15.
9. Linz W, Schoelkens BA, Han Y-F. Beneficial effects of the converting enzyme inhibitor ramipril in ischemic hearts. J Hypertens. 1986;8(suppl 10):S91-S99.
10. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 1984;53:1044-1049.
11. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med. 1987;316: 1429-1435.
12. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
13. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMontte F, Buring J, Hennekens CH. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 1995;332:706-711.
14. Singer DRJ, Missouris CG, Jeffery S. Angiotensin-converting enzyme gene polymorphism: what to do about all the confusion? Circulation. 1996;94:236-239.
15. Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects. J Cardiovasc Pharmacol. 1994;24:S6-S13.
16. Rogerson FM, Chai SY, Schlawe I, Murray WK, Marley PD, Mendelsohn FAO. Presence of angiotensin converting enzyme in the adventitia of large blood vessels. J Hypertens. 1992;10: 615-620.
17. Zhuo J, Allen AM, Yamada H, Sun Y, Mendelsohn FAO. Localization and properties of the angiotensin converting enzyme and angiotensin receptors in the heart. In: Lindpaintner K, Ganten D, eds. The Cardiac Renin-Angiotensin System. New York, NY: Futura Publishing Co Inc; 1994:63-88.
18. 125I-labeled MK351A. J Hypertens. 1984;2:41-44.
19. Friedland J, Silverstein E. A sensitive fluorimetric assay for serum angiotensin converting enzyme. Am J Clin Pathol. 1976; 66:416-424.
20. Kohzuki M, Johnston CI, Chai SY, Jackson B, Perich R, Paxton D, Mendelsohn FAO. Measurement of angiotensin converting enzyme induction and inhibition using quantitative in vitro autoradiography. J Hypertens. 1991;9:579-587.
21. Zhuo J, Casley D, Murone C, Mendelsohn FAO. Acute and chronic in vivo inhibition of angiotensin converting enzyme in the endothelium and adventitia of large arteries and organs of the rabbit. J Cardiovasc Pharmacol. In press.
22. Van Den Berg H, Resplandy G, de Bie AT, Floor W, Bertrand M, Arts CJ. A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of lysine derivative as immunogen to improve the assay specificity. J Pharm Biomed Anal. 1991;9:517-524.
23. Caldwell RPB, Seegal BC, Hsu KC, Das M, Soffer RL. Angiotensin I converting enzyme: vascular endothelial localization. Science. 1976;191:1050-1051.
24. Vanhoutte PM, Boulanger CM, Illiano SC, Nagao T, Vidal M, Mombouli JV. Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol. 1993;22:S10-S16.
25. Pipili E, Manololoulos G, Catravas JD, Maragoudakis ME. Angiotensin converting enzyme activity is present in the endothelium-denuded aorta. Br J Pharmacol. 1989;98:333-335.
26. Pipili-Synetos E, Sideri E, Catravas JD, Maragoudakis ME. Endothelium removal does not abolish angiotensin converting enzyme activity from the mesenteric arterial bed of the rat. Biochem Pharmacol. 1990;40:1149-1151.
27. Saye JA, Singer HA, Peach MJ. Role of endothelium in conversion of angiotensin I to angiotensin II in rabbit aorta. Hypertension. 1984;6:216-221.
28. Mendelsohn FAO, Pubic V, Jackson B, Cubela R, Johnston CI. Acute and chronic effects of perindopril on tissue angiotensin converting enzyme activity. Am J Hypertens. 1991;4:220S-225S.
29. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
30. Brunner HR, Nussberger J, Waeber B. Effects of angiotensin converting enzyme inhibition: a clinical point of view. J Cardiovasc Pharmacol. 1985;7(suppl):S73-S81.
31. Morton JJ, Tree M, Casala-Stenzel J. The effect of captopril on blood pressure and angiotensin I, II. and III in sodium depleted dogs: problems associated with the measurement of angiotensin II after inhibition of converting enzyme. Clin Sci. 1980;58:445-450.
32. Unger T, Moursi M, Ganten D, Hermann K, Lang RE. Antihypertensive action of converting enzyme inhibitor perindopril in spontaneously hypertensive rats: comparison with enalapril and ramipril. J Cardiovasc Pharmacol. 1986;8:276-285.
33. Lees KR, Reid JL. Effects of intravenous 5-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects. J Cardiovasc Pharmacol. 1987;10:129-135.
34. Asmar RG, Pannier B, Laurent T, Benetos A, Daou J, Safar M. Hemodynamic effects of perindopril in essential hypertension. J Hum Hypertens. 1990;4(suppl 4):35-44.
35. Thuillez C, Richard C, Richer C, Loueslati H, Perret L, Auzepy P, Giudicelli J-F. Peripheral hemodynamic effects of perindopril compared in patients with congestive heart failure and in normal volunteers. J Hypertens. 1988;6(suppl 3):S41-S43.